Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25880951 | 0.88 | EPHX2 (0.32) | CA1 | |
| SCHEMBL18948978 | 0.87 | ALDH1A1 (0.35) | CA1 | |
| SCHEMBL25971673 | 0.85 | DNM1 (0.39) | CA1 | |
| SCHEMBL21217045 | 0.83 | ALDH1A1 (0.33) | — | |
| SCHEMBL22509628 | 0.83 | KDM4C (0.33) | CA1 | |
| SCHEMBL13493064 | 0.83 | CA1 (0.34) | CA1 | |
| SCHEMBL21658070 | 0.82 | CA1 (0.31) | CA1 | |
| SCHEMBL25971286 | 0.82 | KDM4C (0.35) | CA1 | |
| SCHEMBL20099358 | 0.80 | — | — | |
| SCHEMBL21868829 | 0.80 | KDM4C (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20210054040-A1 | NOVEL IL-15 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210046160-A1 | Immuno Oncology Combination Therapies With IL-2 Conjugates | Synthorx, Inc. (US) | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210046160-A1 | Immuno Oncology Combination Therapies With IL-2 Conjugates | IL2, IL2RA, IL15 | CA1 4044/4885 |
| US-20210054040-A1 | NOVEL IL-15 CONJUGATES AND USES THEREOF | IL15, IL15RA, IL5 | CA1 3318/4885 |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | CA1 3296/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CA1 4622/4885 |
| US-11707457-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CA1 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.